Indoles as Molecular Growth Instructions: Psilocybin as Conserved Morphogenetic Signal from Deep Ancestry to Neural Execution

Summary

The paper discusses the need for standardized protocols in psilocybin therapy and proposes a dual-drift model to understand psilocybin experiences, distinguishing between two types of psychological elevation. It suggests that psilocybin acts as an intercellular signaling molecule through its compatibility with mammalian receptors, leading to coherent experiences. The findings indicate that psilocybin's effects are self-generated rather than random, supporting therapeutic applications based on neuroplasticity mechanisms.

Study at a glance

Abstract

Abstract Paper 1: Messiah Drift and the Phenomenology of PsilocybinA Dual-Drift Clinical Model and a Mycelial-Signaling Conjecture This paper addresses two gaps that have become urgent as legal psilocybin services expand: the absence of standardized protocols for managing archetypal integration challenges, and the lack of a coherent mechanistic account of why psilocybin experiences exhibit consistent phenomenological structure rather than random noise. The clinical contribution introduces a dual-drift model distinguishing Mystification Drift (elevation of the substance or source to sacred or communicative status) from Messiah Drift (elevation of the self to chosen messenger or uniquely enlightened status). It provides a practical five-step anchoring protocol that facilitators can apply immediately, independent of any particular theoretical framework. The mechanistic hypothesis proposes that psilocybin functions primarily as an intercellular signaling molecule within mycelial networks. Human psychedelic phenomenology arises from cross-kingdom receptor compatibility: conserved indole architecture allows fungal coordination signals to activate mammalian 5-HT2A receptors. Experiences remain entirely self-generated but unfold under altered constraint regimes, producing coherent rather than arbitrary content. The signaling account is presented as the null hypothesis; alternatives require additional assumptions. Testable predictions distinguish it from defense-only models. The paper grounds therapeutic applications in established neuroplasticity mechanisms while offering clear experimental pathways for mycological research. Paper 2: From Indoles to TryptophanReclassification of Physarum polycephalum Deepens the Signaling Hypothesis by 1.5 Billion Years This paper corrects a taxonomic error in earlier work and shows that the correction substantially strengthens, rather than weakens, the hypothesis that tryptophan-derived indole signaling is an ancient, conserved mechanism of biological coordination. Physarum polycephalum, previously grouped with fungi, is now resolved within Amoebozoa—the sister supergroup to Opisthokonta (fungi + animals). The divergence between Amoebozoa and Opisthokonta occurred approximately 1.4–1.6 billion years ago. The paper demonstrates that Physarum engages tryptophan directly through negative chemotaxis, synthesizes it via the conserved shikimate pathway and AROM architecture, possesses an extensive GPCR repertoire, and responds to mammalian neurotransmitters despite lacking a nervous system. These observations push tryptophan-based molecular recognition and signaling architecture back to the last common ancestor of Amoebozoa and Opisthokonta. New developmental evidence is incorporated: psilocybin biosynthetic gene expression (psiD) peaks 395-fold in primordia relative to vegetative mycelium, and psilocybin concentration per unit dry weight decreases consistently with fruiting-body maturity across multiple Psilocybe species. The paper further shows that the chemical-defense hypothesis fails basic empirical tests—psilocybin does not reliably kill, deter, or prevent predation by actual consumers, whereas fungi that evolved true chemical defense (e.g., amatoxins) produce compounds with clear lethal or deterrent effects. The reclassification and supporting data establish indole signaling as an inheritance predating the divergence of major eukaryotic supergroups, not a fungal innovation. Paper 3: Psilocybin as Conserved Morphogenetic SignalThe Growth Instruction, Its Faithful Execution in Neural Tissue, and the Hallucination as Peripheral Render This paper advances a single, integrated conjecture in three ordered movements. First, psilocybin belongs to a family of tryptophan-derived indole signaling molecules conserved across kingdoms—auxin in plants, serotonin and melatonin in animals, the psilocybin family in fungi—whose recurring ancestral role is the coordination of growth and morphogenesis. Second, when a mammal ingests psilocybin, the conserved growth instruction is read by neural tissue fluent in the ancient signal through shared indole-receptor architecture and is executed as dendritic and synaptic growth—the documented neuroplasticity of psilocybin. Third, the visual cortex, which bears the receptor but was never the intended addressee of a growth signal optimized for fractal mycelial networks, renders its best approximation of the instruction it receives, producing the ordered, recursive, space-filling fractal geometry characteristic of the psilocybin experience. The framework unifies mycelial coordination requirements, hyphal-knot formation as growth-pattern execution, dendritic sprouting as the same instruction in different substrate, fractal visual phenomenology as literal rendering, therapeutic neuroplasticity independent of mystical interpretation, and thermal economy of high-dose effects. It generates specific, testable predictions (including correlations between dendritic spine density and subjective intensity, and neural temperature elevation with plasticity-window duration) while separating the growth mechanism (primary, physiologically grounded) from the hallucinatory render (peripheral, substrate-dependent). The paper builds directly on the clinical protocols and deep-ancestry evidence established in the preceding works of the series. Paper 4: A Deterrent That Does Not DeterReconsidering Chemical Defence as the Function of Psilocybin, and Why the Deterrence Question Is Malformed This paper examines the long-standing default hypothesis that psilocybin evolved primarily as a chemical defense against fungivores and argues that both the hypothesis and the experimental designs used to test it are structurally flawed. Defense is a coevolutionary claim requiring differential effects between naïve generalists and coevolved specialists, plus evidence that the metabolite was selected because it reduced fitness costs imposed by actual consumers. Recent laboratory work feeding Psilocybe material to Drosophila larvae (a naïve frugivore with no evolutionary history with these mushrooms) is shown to be incapable of adjudicating this claim. The study’s own controls and field data undermine a psilocybin-specific defensive interpretation: non-psychedelic mushroom tissue reproduces a substantial fraction of the observed harm; receptor-knockdown lines were not protected (and were sometimes more affected); and actual specialist mycophages thrive on and develop within Psilocybe tissue in nature. More fundamentally, the paper demonstrates that the question “Is psilocybin a deterrent?” is malformed. A genuine evolved chemical defense carries fixed valence—it harms receivers regardless of psychology. Psilocybin’s effects are receiver-dependent and reversible (aversive to some organisms, attractive or neutral to others, including humans who cultivate the mushrooms for the very effect). Primary defenses in the same fungal lineage (amatoxins) do not reverse valence. The paper concludes that deterrence is at most a peripheral consequence of a molecule whose primary function is intercellular signaling and growth coordination within mycelial networks. It offers clear criteria for future experiments that could distinguish signaling from defense and treats the recent empirical work as an invitation to better-designed tests rather than settled support for the default view. Paper 5: Growth on DemandAn Avenue for Investigating Indole-Driven Neuroplasticity as Mitigation of Iatrogenic and Disease-Related Neural Damage — A Proposal This paper takes the mechanistic reading developed across the series—one in which psilocybin and related indoles function as conserved signals whose primary effect is the coordination of growth—and derives a modest, testable clinical hypothesis. If these compounds reliably open a time-limited window of directed neural growth (as established by the depression literature on BDNF upregulation, dendritic spine formation, and network reorganization), then a controlled induction of that window around damaging events could support compensatory reorganization. The claim is deliberately narrow: not cure or reversal of lost tissue, but mitigation of net functional deficit through rerouting of function around damage via surviving circuits. Target contexts include perioperative neurosurgery, neurotoxic medications, traumatic brain injury, and early neurodegenerative processes. The paper outlines the shape of a controlled trial (defined growth-window schedule versus standard care, functional outcome measures at specified intervals) and states the falsifiable prediction: reduced net functional deficit in the treated arm. It notes that non-hallucinogenic engineered analogues preserving the growth-inducing action would, on this reading, be a natural clinical development path, since the growth effect is primary and the subjective experience peripheral. The proposal is offered as the lightest-weight and most forward-looking paper in the series—an empirical avenue worth investigating rather than a claim of demonstrated benefit beyond the existing depression evidence.

Tags